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There is a growing interest in discovery and development of new therapeutics that will cure 
chronic hepatitis B virus (HBV) infection, due to the recent establishment of new cell culture-
based and small animal-based models.  These new systems create unprecedented 
opportunities to study the entire viral life cycle and to search for vulnerabilities that can be 
exploited for curative purposes. Here we propose a scientific pathway that we believe will lead 
to the development of curative therapies for chronic HBV infection and its associated diseases.   
HBV is an hepatotropic, non-cytopathic, partially double-stranded DNA virus that replicates by 
reverse transcription of a greater-than-genome-length RNA and causes acute and chronic 
necro-inflammatory liver disease (hepatitis), cirrhosis of the liver, liver failure, death and 
hepatocellular carcinoma.(1, 2) Approximately 2 billion people alive today have been infected by 
HBV and have residual virus in their liver, 250 million of whom are currently chronically-infected 
with HBsAg+.(3, 4) Antiviral drugs that suppress viral replication and retard disease progression 
are available; however, treatment is generally not curative, is life-long, expensive and limited by 
the extent to which it reduces the risk of death due to liver disease. A highly effective protective 
vaccine is available, leading the World Health Organization and the National Academies of 
Science, Engineering and Medicine to recently declare that elimination of HBV is possible if a 
curative therapy can be developed to supplement the protective effect of the vaccine.(3, 5, 6) This 
document introduces the challenge and presents a roadmap for the discovery of a cure. 
Development of a cure for any viral infection requires a sufficiently deep understanding of the 
virus life cycle and its interaction with the host to identify vulnerabilities that can be exploited to 
eradicate it from infected cells. The key word here is eradicate. In general, these viral mediated 
steps include entry, uncoating, establishment and maintenance of a transcriptional template in 
the nucleus (cccDNA), transcription, translation, replication, assembly, transport and release 
and nucleus reentry of capsid encoated viral particles. Eradication also requires engagement of 
the host immune response to control viral spread from any residual infected cells and to 
counteract any evasive strategies deployed by the virus to defeat the host response and assist 
in clearance of virally infected cells.  
Despite its discovery 50 years ago, most steps in the HBV life cycle and the nature of its 
interaction with its host are only partially understood because the experimental systems 
required for such experiments have not been available.(7) Furthermore, despite the ability of 
currently available direct acting antiviral drugs to suppress HBV DNA replication, they are rarely 
curative because they do not prevent the establishment or maintenance of the long-lived HBV 
cccDNA transcriptional template--the stable nuclear form of the viral genome, which must be 
eliminated or permanently silenced to achieve a durable HBV cure.(8)   
Luckily, experimental systems that permit detailed analysis of cccDNA biogenesis, homeostasis 
and decay, and all other steps in the viral life cycle were recently developed.(9)  Thus, we are 
now on the threshold of a period of exploration that, if focused on eliminating the cccDNA 
transcriptional template of the virus, could lead to a cure of chronic HBV infection, once and for 
all.  
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We encourage the scientific community to focus on research leading to discovery of a cure for 
chronic HBV infection based on these principles, as summarized here and highlighted as 
illustrations in Fig. 1: 
• The surest way to cure HBV is to eliminate or permanently silence its cccDNA. 
 
• The most important impediment to this achievement is our limited understanding of the 
fundamental molecular mechanisms that control cccDNA biogenesis, homeostasis and 
decay. 
 
• Understanding these mysteries is now within reach, thanks to recent technological 
advances that enable definition of these mechanisms. 
 
• Vulnerabilities in the cccDNA “life cycle” that are discovered in the course of these 
studies can be exploited to develop small molecule and other molecular strategies to 
eradicate or permanently silence the cccDNA. 
 
• Because these studies will explore the unknown, the outcome, like all great adventures, 
cannot be predicted. Thus, we suggest that in addition to approaches that directly target 
cccDNA, independent approaches that target other vulnerabilities in the viral life cycle 
and either indirectly repress HBV cccDNA or safely establish a curative antiviral immune 
response, be pursued in parallel.  
 
• Such projects could include genetic approaches to cccDNA mutagenesis (e.g. 
CRISPR/Cas9), epigenetic modification, or other strategies that can suppress cccDNA 
transcription (e.g. HBV-targeted antisense and siRNA, HBx-inhibition, etc.) or to prevent 
its recycling (e.g. capsid inhibitors). 
 
Of course, a vigorous basic and translational research effort to better define the nature of the 
immune response to HBV in chronically infected patients is also essential.  Ideally, the antibody 
response would be examined at the single B cell level to reveal the extent to which neutralizing 
antibodies are produced by chronically infected patients and to predict whether patients who are 
“cured” of HBV by direct acting antivirals will require active immunization to prevent intrahepatic 
viral spread from any infected cells that remain after treatment, and to protect them from future 
exposure. 
Similarly, the functional and phenotypic characteristics of the HBV-specific T cell response must 
be studied before, during and after curative treatment to determine the extent to which it 
contributes to the durability or the failure of a given therapeutic strategy. In addition, immune-
based strategies that induce T cell-mediated selective elimination of HBV-infected cells, 
antibody-mediated delivery of antiviral effector molecules to infected cells, T cell checkpoint 
inhibition, CAR-T cell infusion, among others, should be explored.   
These studies should be iterative, where results from the clinical work guide the laboratory work, 
and vice versa. In this way, the immunobiology, number of infected cells, and other clinical 
parameters of chronic hepatitis B as a function of medical intervention, can be followed. 
We also note that hepatocellular carcinoma (HCC) can be a consequence of chronic hepatitis B. 
Therefore, to comprehensively address the problems associated with chronic viral hepatitis B, 
an improved understanding of the molecular basis of HCC to guide early detection and 
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treatment is vital.  Clinical collaborative networks should also be reinforced and expanded to 
allow for evaluation of new early detection strategies of HCC and therapeutics of HCC and HBV.  
 
It is also important to note that any intervention that directly or indirectly activates the cytotoxic T 
cell response to HBV could kill all the infected hepatocytes. This would be good if only a few 
hepatocytes in a given patient are infected and the functional hepatic reserve in that patient is 
robust. On the other hand, it could be fatal, inducing an acute on chronic liver disease event 
(ACLD), if many hepatocytes are infected and hepatic reserve is tenuous. Thus, if the cytotoxic 
T cell response is activated by any therapeutic intervention, it must be in a “Goldilocks zone” 
where it kills just enough hepatocytes at just the right rate to clear the infection without either 
triggering acute hepatic insufficiency or worsening the underlying chronic liver disease. It is 
imperative, therefore, to do these studies if we hope to predict how infected patients will 
respond immunologically to curative therapy before treatment begins, keeping in mind that the 
physician’s first responsibility is “primum non nocere,” first, do no harm. 
A recent review article from Revill et al (2016) specified broad goals for HBV research and has 
since led to the establishment of an international coalition of scientists, clinicians and 
stakeholders, committed to the elimination of hepatitis B virus, (ICE-HBV) (http://ice-hbv.org/).(10)  
Our intention is to support and build upon their report and effort by adding detail to create a 
roadmap for policy makers from government and other funding institutions, and for planning 
long-term research.  
A cure for hepatitis B is also likely to greatly reduce morbidity and mortality associated with 
hepatitis delta (HBD) virus infection, end-stage liver disease and HCC, although it is appreciated 
that these clinical problems deserve a specific research agenda of their own. 
It is clearly important to explore multiple viral gene products and life cycle steps for intervention 
opportunities. To date,  of all the candidate approaches considered, elimination of HBV cccDNA 
is most likely to produce a durable cure of chronic HBV infection, after a finite course of antiviral 
therapy. The extent to which this can be achieved with drugs, biologicals, genetic manipulations, 
immunomodulation, etc., is the major question to be answered. While transcriptional silencing of 
cccDNA may be easier to achieve than physical cccDNA elimination, it would probably require 
lifelong treatment to produce lifelong effects unless it triggers some unpredictable durable 
downstream effect like immune-mediated destruction or non-cytolytic elimination of cccDNA 
from the infected cells.  Thus, a vigorous, comprehensive, adequately funded, research effort, 
involving multiple, complementary approaches must be taken, with the results being shared, in 
the public domain, as quickly as possible.    
Luckily, experimental systems that permit detailed analysis of the cccDNA and other steps in the 
viral life cycle are now available to the scientific community for these challenges. In our opinion, 
a concerted discovery effort that is both encouraged and enabled by governmental and 
nongovernmental funding agencies can make a huge difference in the lives of hundreds of 
millions of people worldwide. Let’s not let this chance to do so much good slip away. 
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FIGURE LEGEND 
Hepatitis B virus (HBV)  life cycle, emphasizing opportunities to suppress viral cccDNA 
and restore immune control. Host and viral functions that could be exploited for therapeutic 
purposes are illustrated, beginning with binding of the virus to the NTCP receptor on 
hepatocytes(1), followed by translocation of the nucleocapsid to the nucleus and formation of 
cccDNA (2) and synthesis steps (3), (4), leading to either egress  (6) of newly formed virions or 
return of nucleo-capsids to the nucleus (7).  Opportunities for cccDNA suppression and immune 
control are categorized as either acting upon the viral gene products (white boxed text) or acting 
upon host innate and adaptive immune systems (green boxed text), noting that in many cases 
these different pathways overlap.  Humoral responses are also indicated (Abs, Y). Orange, red 
brown circles (Small, SHBs, Medium, MHBs, Large, LHBs, respectively); yellow triangle (core 
protein), blue circle (pol), “X” (x protein), red semi circles, cccDNA and black line, HBV 3.2 kb 
and sub genomic HBV RNA; 22 nM spheres, rods, and 42 nM virions are also illustrated. The 
examples of virus life cycle steps and immune modulators are representative and not 
comprehensive.   TLR3 is shown since it is present in hepatocytes, but other TLR receptors may 
also be exploited therapeutically. 
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